Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bossard Holding Ord Shs BHAGF

Bossard Holding AG is a Switzerland-based holding company of the Bossard Group specialized in the procurement and sale of fastening elements. Through its operating entities, the Company focuses on the procurements of fasteners, including sales, technical and engineering support and inventory management. The Company’s business model covers three strategic areas: Product Solutions, providing product line, which covers standard parts, components developed in-house, branded products, as well as special parts; Application Engineering, which includes technical advice, and Customer Logistics, which offers logistic solutions. The Company has approximately 50 locations worldwide. The Company’s products include Bossard ecosyn, screws and fastening elements, standard fasteners, custom-made screws, nut and bolts for special uses and brand-name fasteners. The Company operates through its subsidiaries in Europe, America and Aisia.


PINL:BHAGF - Post by User

Post by Iseneschalon Nov 28, 2023 8:52am
131 Views
Post# 35755851

SEEL.....Read the previous posts (make note 2021)...now this

SEEL.....Read the previous posts (make note 2021)...now this

Seelos Therapeutics Announces 1-for-30 Reverse Stock Split

2023-11-24 07:53 ET - News Release

NEW YORKNov. 24, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its Board of Directors approved a 1-for-30 a reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on Tuesday, November 28, 2023.

 
 

 

 

 

 
<< Previous
Bullboard Posts
Next >>